Clostridium difficile and methicillin-resistant Staphylococcus aureus: Emerging concepts in vaccine development

Annual Review of Medicine

Volumn 62, Issue , 2011, Pages 201-215

  Kaslow, David C ^a   Shiver, John W ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

CINV; delirium; methadone; neuropathic pain; palliative care; POLST; quality of life

Indexed keywords

BACTERIAL VACCINE; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; COMPLEMENT FIXING ANTIBODY; MEMBRANE ANTIGEN; PANTON VALENTINE LEUKOCIDIN; VIRULENCE FACTOR;

ADAPTIVE IMMUNITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; CELLULAR IMMUNITY; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED PNEUMONIA; EPIDEMIC; HIGH RISK POPULATION; HOSPITAL INFECTION; HUMAN; IMMUNIZATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RISK FACTOR; TH1 CELL; TH17 CELL;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL VACCINES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FEMALE; HUMANS; IMMUNITY, CELLULAR; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL VACCINES; TH1 CELLS; TH17 CELLS; VIRULENCE FACTORS;

EID: 79551601622     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev-med-051109-101544     Document Type: Article

References (117)

1. Hall IC, O'Toole E. 1935. Intestinal flora in new-born infants: with a description of a new pathogenic anaerobe, Bacillus difficilis. Am. J. Dis. Child 49:390-402
2. Ogston A. 1880. Uber Abscesse. Arch. Klin. Chir. 25:588-600
3. Health Protection Agency. 2009. Healthcare-Associated Infections in England: 2008-2009 report. http:// www.hpa.org.uk/web/HPAwebFile/HPAweb-C/ 1252326222452
4. Miller BA, Chen LF, Sexton DJ, Anderson DJ. 2010. The impact of hospital-onset healthcare facility associated (HO-HCFA) Clostridium difficile infection (CDI) in community hospitals: surpassing methicillin-resistant Staphylococcus aureus (MRSA) as the new superbug. Presented at Int. Conf. Healthcare-Assoc. Infect., 5th Decennial, Atlanta, GA, Mar. 18-22, Abstr. 386. http://shea.confex.com/shea/2010/ webprogram/Paper2801.html
5. Shinefield HR, Ruff NL. 2009. Staphylococcal infections: a historical perspective. Infect. Dis. Clin. North Am. 23:1-15
6. Deleo FR, Otto M, Kreiswirth BN, Chambers HF. 2010. Community-associated meticillin-resistant Staphylococcus aureus. Lancet 375:1557-68
7. Schaffer AC, Lee JC. 2009. Staphylococcal vaccines and immunotherapies. Infect. Dis. Clin. North Am. 23:153-71
8. Holtfreter S, Kolata J, Broker BM. 2010. Towards the immune proteome of Staphylococcus aureus-the anti-S. aureus antibody response. Int. J. Med. Microbiol. 300:176-92
9. Voth DE, Ballard JD. 2005. Clostridium difficile toxins: mechanism of action and role in disease. Clin. Microbiol. Rev. 18:247-63
10. Gerding DN. 2009. Clostridium difficile 30 years on: What has, or has not, changed and why? Int. J. Antimicrob. Agents 33(Suppl. 1):S2-8
11. Bryant K, McDonald LC. 2009. Clostridium difficile infections in children. Pediatr. Infect. Dis. J. 28:145-46
12. Hookman P, Barkin JS. 2009. Clostridium difficile associated infection, diarrhea and colitis. World J. Gastroenterol. 15:1554-80
13. Hu MY, Katchar K, Kyne L, et al. 2009. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology 136:1206-14
14. Henrich TJ, Krakower D, Bitton A, Yokoe DS. 2009. Clinical risk factors for severe Clostridium difficile-associated disease. Emerg. Infect. Dis. 15:415-22
15. Richardson SA, Alcock PA, Gray J. 1983. Clostridium difficile and its toxin in healthy neonates. Br. Med. J. (Clin. Res. Ed.) 287:878
16. Viscidi R, Laughon BE, Yolken R, et al. 1983. Serum antibody response to toxins A and B of Clostridium difficile. J. Infect. Dis. 148:93-100
17. Viscidi R, Willey S, Bartlett JG. 1981. Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterology 81:5-9
18. George WL, Sutter VL, Citron D, Finegold SM. 1979. Selective and differential medium for isolation of Clostridium difficile. J. Clin. Microbiol. 9:214-19
19. Delmee M, Van Broeck J, Simon A, et al. 2005. Laboratory diagnosis of Clostridium difficile-associated diarrhoea: a plea for culture. J. Med. Microbiol. 54:187-91
20. McFarland LV, Brandmarker SA, Guandalini S. 2000. Pediatric Clostridium difficile: a phantom menace or clinical reality? J. Pediatr. Gastroenterol. Nutr. 31:220-31
21. Eglow R, Pothoulakis C, Itzkowitz S, et al. 1992. Diminished Clostridium difficile toxin A sensitivity in newborn rabbit ileum is associated with decreased toxin A receptor. J. Clin. Invest. 90:822-29
22. Keel MK, Songer JG. 2007. The distribution and density of Clostridium difficile toxin receptors on the intestinal mucosa of neonatal pigs. Vet. Pathol. Online 44:814-22
23. McDonald LC, Killgore GE, Thompson A, et al. 2005. An epidemic, toxin gene-variant strain of Clostrid-ium difficile. N. Engl. J. Med. 353:2433-41
24. Goorhuis A, Bakker D, Corver J, et al. 2008. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin. Infect. Dis. 47:1162-70
25. Warny M, Pepin J, Fang A, et al. 2005. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366:1079-84
26. Centers for Disease Control and Prevention. 2005. Severe Clostridium difficile-associated disease in populations previously at low risk-four states, 2005. MMWR 54:1201-5
27. Morgan OW, Rodrigues B, Elston T, et al. 2008. Clinical severity of Clostridium difficile PCR ribotype 027: a case-case study. PLoS One 3:e1812
28. Benson L, Song X, Campos J, Singh N. 2007. Changing epidemiology of Clostridium difficile-associated disease in children. Infect. Control Hosp. Epidemiol. 28:1233-35
29. Zilberberg MD, Tillotson GS, McDonald C. 2010. Clostridium difficile infections among hospitalized children, United States, 1997-2006. Emerg. Infect. Dis. 16:604-9
30. Hurst V. 1957. Staphylococcus aureus in the infant upper respiratory tract. I. Observations on hospital-born babies. J. Hyg. (Lond.) 55:299-312
31. Kuehnert MJ, Kruszon-Moran D, Hill HA, et al. 2006. Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001-2002. J. Infect. Dis. 193:172-79
32. Graham PL 3rd, Lin SX, Larson EL. 2006. A U.S. population-based survey of Staphylococcus aureus colonization. Ann. Intern. Med. 144:318-25
33. Von Eiff C, Becker K, Machka K, et al. 2001. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N. Engl. J. Med. 344:11-16
34. Wertheim HF, Melles DC, Vos MC, et al. 2005. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect. Dis. 5:751-62
35. Shinefield HR, Ribble JC, Boris M, Eichenwald HF. 1963. Bacterial interference: its effect on nursery-acquired infection with Staphylococcus aureus. I. Preliminary observations on artificial colonization of newborns. Am. J. Dis. Child 105:646-54
36. Boris M, Sellers TF Jr, Eichenwald HF, et al. 1964. Bacterial interference; protection of adults against nasal Staphylococcus aureus infection after colonization with a heterologous S. aureus strain. Am. J. Dis. Child 108:252-61
37. Bode LG, Kluytmans JA, Wertheim HF, et al. 2010. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N. Engl. J. Med. 362:9-17
38. Wertheim HF, Vos MC, Ott A, et al. 2004. Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet 364:703-5
39. Barber M. 1947. Staphylococcal infection due to penicillin-resistant strains. BMJ 2:863-65
40. Robinson DA, Kearns AM, Holmes A, et al. 2005. Re-emergence of early pandemic Staphylococcus aureus as a community-acquired meticillin-resistant clone. Lancet 365:1256-58
41. Jessen O, Rosendal K, Bulow P, et al. 1969. Changing staphylococci and staphylococcal infections. A ten-year study of bacteria and cases of bacteremia. N. Engl. J. Med. 281:627-35
42. Healy CM, Hulten KG, Palazzi DL, et al. 2004. Emergence of new strains of methicillin-resistant Staphylococcus aureus in a neonatal intensive care unit. Clin. Infect. Dis. 39:1460-66
43. Kennedy AD, Otto M, Braughton KR, et al. 2008. Epidemic community-associated methicillin-resistant Staphylococcus aureus: recent clonal expansion and diversification. Proc. Natl. Acad. Sci. USA 105:1327-32
44. Maree CL, Daum RS, Boyle-Vavra S, et al. 2007. Community-associated methicillin-resistant Staphylo-coccus aureus isolates causing healthcare-associated infections. Emerg. Infect. Dis. 13:236-42
45. Klevens RM, Morrison MA, Fridkin SK, et al. 2006. Community-associated methicillin-resistant Staphy-lococcus aureus and healthcare risk factors. Emerg. Infect. Dis. 12:1991-93
46. Centers for Disease Control and Prevention. 2010. ABCs report: methicillin-resistant Staphylococ-cus aureus, 2008. Active Bacterial Core surveillance. http://www.cdc.gov/abcs/reports-findings/ survreports/mrsa08.html
47. Jank T, Giesemann T, Aktories K. 2007. Rho-glucosylating Clostridium difficile toxins A and B: new insights into structure and function. Glycobiology 17:15R-22R
48. Popoff MR, Rubin EJ, Gill DM, Boquet P. 1988. Actin-specific ADP-ribosyltransferase produced by a Clostridium difficile strain. Infect. Immun. 56:2299-306
49. Goncalves C, Decre D, Barbut F, et al. 2004. Prevalence and characterization of a binary toxin (actin-specific ADP-ribosyltransferase) from Clostridium difficile. J. Clin. Microbiol. 42:1933-39
50. Barbut F, Decre D, Lalande V, et al. 2005. Clinical features of Clostridium difficile-associated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)-producing strains. J. Med. Microbiol. 54:181-85
51. Savidge TC, Pan WH, Newman P, et al. 2003. Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine. Gastroenterology 125:413-20
52. Shim JK, Johnson S, Samore MH, et al. 1998. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 351:633-36
53. Johnson S, Sambol SP, Brazier JS, et al. 2003. International typing study of toxin A-negative, toxin B-positive Clostridium difficile variants. J. Clin. Microbiol. 41:1543-47
54. Drudy D, Fanning S, Kyne L. 2007. Toxin A-negative, toxin B-positive Clostridium difficile. Int. J. Infect. Dis. 11:5-10
55. Lyras D, O'Connor JR, Howarth PM, et al. 2009. Toxin B is essential for virulence of Clostridium difficile. Nature 458:1176-79
56. Kyne L, Warny M, Qamar A, Kelly CP. 2000. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N. Engl. J. Med. 342:390-97
57. Kyne L, Warny M, Qamar A, Kelly CP. 2001. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 357:189-93
58. Leav BA, Blair B, Leney M, et al. 2010. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 28:965-69
59. Giannasca PJ, Warny M. 2004. Active and passive immunization against Clostridium difficile diarrhea and colitis. Vaccine 22:848-56
60. Giannasca PJ, Zhang ZX, Lei WD, et al. 1999. Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect. Immun. 67:527-38
61. Babcock GJ, Broering TJ, Hernandez HJ, et al. 2006. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect. Immun. 74:6339-47
62. Aboudola S, Kotloff KL, Kyne L, et al. 2003. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect. Immun. 71:1608-10
63. Sougioultzis S, Kyne L, Drudy D, et al. 2005. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 128:764-70
64. Lowy I, Molrine DC, Leav BA, et al. 2010. Treatment with monoclonal antibodies against Clostridium difficile toxins. N. Engl. J. Med. 362:197-205
65. Pantosti A, Cerquetti M, Viti F, et al. 1989. Immunoblot analysis of serum immunoglobulin G response to surface proteins of Clostridium difficile in patients with antibiotic-associated diarrhea. J. Clin. Microbiol. 27:2594-97
66. Mulligan ME, Miller SD, McFarland LV, et al. 1993. Elevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile. Clin. Infect. Dis. 16(Suppl. 4):S239-44
67. Sánchez-Hurtado K, Corretge M, Mutlu E, et al. 2008. Systemic antibody response to Clostridium difficile in colonized patients with and without symptoms and matched controls. J. Med. Microbiol. 57:717-24
68. Péchiné S, Gleizes A, Janoir C, et al. 2005. Immunological properties of surface proteins of Clostridium difficile. J. Med. Microbiol. 54:193-96
69. Waligora A-J, Hennequin C, Mullany P, et al. 2001. Characterization of a cell surface protein of Clostrid-ium difficile with adhesive properties. Infect. Immun. 69:2144-53
70. Tasteyre A, Barc M-C, Collignon A, et al. 2001. Role of FliC and FliD flagellar proteins of Clostridium difficile in adherence and gut colonization. Infect. Immun. 69:7937-40
71. Hennequin C, Janoir C, Barc M-C, et al. 2003. Identification and characterization of a fibronectin-binding protein from Clostridium difficile. Microbiology 149:2779-87
72. Drudy D, Calabi E, Kyne L, et al. 2004. Human antibody response to surface layer proteins in Clostridium difficile infection. FEMS Immunol. Med. Microbiol. 41:237-42
73. Calabi E, Calabi F, Phillips AD, Fairweather NF. 2002. Binding of Clostridium difficile surface layer proteins to gastrointestinal tissues. Infect. Immun. 70:5770-78
74. Wright A, Drudy D, Kyne L, et al. 2008. Immunoreactive cell wall proteins of Clostridium difficile identified by human sera. J. Med. Microbiol. 57:750-56
75. O'Brien JB, McCabe MS, Athie-Morales V, et al. 2005. Passive immunisation of hamsters against Clostrid-ium difficile infection using antibodies to surface layer proteins. FEMS Microbiol. Lett. 246:199-205
76. Ni Eidhin DB, O'Brien JB, McCabe MS, et al. 2008. Active immunization of hamsters against Clostridium difficile infection using surface-layer protein. FEMS Immunol. Med. Microbiol. 52:207-18
77. Lin L, Ibrahim AS, Xu X, et al. 2009. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog. 5:e1000703
78. Herold BC, Immergluck LC, Maranan MC, et al. 1998. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 279:593-98
79. Klein E, Smith DL, Laxminarayan R. 2009. Community-associated methicillin-resistant Staphylococcus aureus in outpatients, United States, 1999-2006. Emerg. Infect. Dis. 15:1925-30
80. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. 2006. Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. 355:666-74
81. Miller LG, Perdreau-Remington F, Rieg G, et al. 2005. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N. Engl. J. Med. 352:1445-53
82. Gillet Y, Issartel B, Vanhems P, et al. 2002. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 359:753-59
83. Graves SF, Kobayashi SD, DeLeo FR. 2010. Community-associated methicillin-resistant Staphylococcus aureus immune evasion and virulence. J. Mol. Med. 88:109-14
84. Diep BA, Otto M. 2008. The role of virulence determinants in community-associated MRSA pathogen-esis. Trends Microbiol. 16:361-69
85. Okuma K, Iwakawa K, Turnidge JD, et al. 2002. Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community. J. Clin. Microbiol. 40:4289-94
86. Li M, Diep BA, Villaruz AE, et al. 2009. Evolution of virulence in epidemic community-associated methicillin-resistant Staphylococcus aureus. Proc. Natl. Acad. Sci. 106:5883-88
87. Montgomery CP, Boyle-Vavra S, Daum RS. 2009. The arginine catabolic mobile element is not associated with enhanced virulence in experimental invasive disease caused by the community-associated methicillin-resistant Staphylococcus aureus USA300 genetic background. Infect. Immun. 77:2650-56
88. Diep BA, Stone GG, Basuino L, et al. 2008. The arginine catabolic mobile element and staphylococcal chromosomal cassette mec linkage: convergence of virulence and resistance in the USA300 clone of methicillin-resistant Staphylococcus aureus. J. Infect. Dis. 197:1523-30
89. Vandenesch F, Naimi T, Enright MC, et al. 2003. Community-acquired methicillin-resistant Staphy-lococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg. Infect. Dis. 9:978-84
90. Gladstone GP, Van Heyningen WE. 1957. Staphylococcal leucocidins. Br. J. Exp. Pathol. 38:123-37
91. Francis JS, Doherty MC, Lopatin U, et al. 2005. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin. Infect. Dis. 40:100-7
92. Loffler B, Hussain M, Gundmeier M, et al. 2010. Staphylococcus aureus Panton-Valentine leukocidin is a very potent cytoxic factor for human neutrophils. PLoS Pathol. 6:1-12
93. Villaruz AE, Bubeck Wardenburg J, Khan BA, et al. 2009. A point mutation in the agr locus rather than expression of the Panton-Valentine leukocidin caused previously reported phenotypes in Staphylococcus aureus pneumonia and gene regulation. J. Infect. Dis. 200:724-34
94. Bubeck Wardenburg J,Schneewind O. 2008. Vaccine protection againstStaphylococcus aureus pneumonia. J. Exp. Med. 205:287-94
95. Brown EL, Dumitrescu O, Thomas D, et al. 2009. The Panton-Valentine leukocidin vaccine protects mice against lung and skin infections caused by Staphylococcus aureus USA300. Clin. Microbiol. Infect. 15:156-64
96. Vandenesch F, Couzon F, Boisset S, et al. 2010. The Panton-Valentine leukocidin is a virulence factor in a murine model of necrotizing pneumonia. J. Infect. Dis. 201:967-69; author reply 969-70
97. Yoong P, Pier GB. 2010. Antibody-mediated enhancement of community-acquired methicillin-resistant Staphylococcus aureus infection. Proc. Natl. Acad. Sci. 107:2241-46
98. Otter JA, French GL. 2010. Molecular epidemiology of community-associated meticillin-resistant Staphylococcus aureus in Europe. Lancet Infect. Dis. 10:227-39
99. Recsei P, Kreiswirth B, O'Reilly M, et al. 1986. Regulation of exoprotein gene expression in Staphylococcus aureus by agr. Mol. Gen. Genet. 202:58-61
100. Bhakdi S, Tranum-Jensen J. 1991. Alpha-toxin of Staphylococcus aureus. Microbiol. Rev. 55:733-51
101. Wang R, Braughton KR, Kretschmer D, et al. 2007. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat. Med. 13:1510-14
102. Park J, Jagasia R, Kaufmann GF, et al. 2007. Infection control by antibody disruption of bacterial quorum sensing signaling. Chem. Biol. 14:1119-27
103. Adlam C, Ward PD, McCartney AC, et al. 1977. Effect of immunization with highly purified alpha- and beta-toxins on staphylococcal mastitis in rabbits. Infect. Immun. 17:250-56
104. Spellberg B, Ibrahim AS, Yeaman MR, et al. 2008. The antifungal vaccine derived from the recombinant N terminus of Als3p protects mice against the bacterium Staphylococcus aureus. Infect. Immun. 76:4574-80
105. Lekstrom-Himes JA, Gallin JI. 2000. Immunodeficiency diseases caused by defects in phagocytes. N. Engl. J. Med. 343:1703-14
106. Segal BH, Leto TL, Gallin JI, et al. 2000. Genetic, biochemical, and clinical features of chronic granu-lomatous disease. Medicine (Baltimore) 79:170-200
107. Harrington LE, Hatton RD, Mangan PR, et al. 2005. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6:1123-32
108. Park H, Li Z, Yang XO, et al. 2005. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6:1133-41
109. Zhu J, Paul WE. 2010. Heterogeneity and plasticity of T helper cells. Cell Res. 20:4-12
110. Ochs HD, Oukka M, Torgerson TR. 2009. TH17 cells and regulatory T cells in primary immunodeficiency diseases. J. Allergy Clin. Immunol. 123:977-85
111. Davis SD, Schaller J, Wedgwood RJ. 1966. Job's syndrome. Recurrent, "cold", staphylococcal abscesses. Lancet 1:1013-15
112. Holland SM, DeLeo FR, Elloumi HZ, et al. 2007. STAT3 mutations in the hyper-IgE syndrome. N. Engl. J. Med. 357:1608-19
113. Milner JD, Brenchley JM, Laurence A, et al. 2008. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 452:773-76
114. Ma CS, Chew GY, Simpson N, et al. 2008. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J. Exp. Med. 205:1551-57
115. Matsuzaki G, Umemura M. 2007. Interleukin-17 as an effector molecule of innate and acquired immunity against infections. Microbiol. Immunol. 51:1139-47
116. Arroyo LG, Kruth SA, Willey BM, et al. 2005. PCR ribotyping of Clostridium difficile isolates originating from human and animal sources. J. Med. Microbiol. 54:163-66
117. McFarland LV, Mulligan ME, Kwok RY, Stamm WE. 1989. Nosocomial acquisition of Clostridium difficile infection. N. Engl. J. Med. 320:204-10